Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

RARE Ultragenyx Pharmaceutical

Watchlist
45.890
-1.750-3.67%
Trading Session  02/08 11:49 ET
High
47.650
Open
47.650
Turnover
4.26M
Low
45.715
Pre Close
47.640
Volume
91.75K
Market Cap
3.22B
P/E(TTM)
Loss
52wk High
85.530
Shares
70.11M
P/E(Static)
Loss
52wk Low
33.360
Float Cap
3.06B
Bid/Ask %
0.00%
Historical High
179.647
Shs Float
66.75M
Volume Ratio
0.43
Historical Low
31.990
Dividend TTM
--
Div Yield TTM
--
P/B
6.86
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.14%
Amplitude
4.06%
Avg Price
46.404
Lot Size
1
Float Cap
3.06B
Bid/Ask %
0.00%
Historical High
179.647
Shs Float
66.75M
Volume Ratio
0.43
Historical Low
31.990
Dividend TTM
--
P/B
6.86
Dividend LFY
--
Turnover Ratio
0.14%
Amplitude
4.06%
Avg Price
46.404
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010, and is headquartered in Novato, CA.
CEO: Dr. Emil D. Kakkis,M.D.
Market: NASDAQ
Listing Date: 01/31/2014
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist